https://doi.org/10.4081/aiua.2016.2.81
0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Prognostic impact of ReTURB in high grade T1 primary bladder cancer

Authors

Roberto Sanseverino
U.O.C. di Urologia, Ospedale Umberto I, ASL Salerno, Nocera Inferiore, Italy.
Giorgio Napodano
giorgio.napodano@gmail.com
U.O.C. di Urologia, Ospedale Umberto I, ASL Salerno, Nocera Inferiore, Italy.
Antonio Campitelli
U.O.C. di Urologia, Ospedale Umberto I, ASL Salerno, Nocera Inferiore, Italy.
Maria Addesso
U.O.C. di Anatomia Patologica, Ospedale Umberto I, ASL Salerno, Nocera Inferiore, Italy.
Purpose: To evaluate whether pathological outcomes of ReTURB have a prognostic impact on recurrence and progression of primitive T1HG bladder cancer. Material and methods: Patients affected by primitive T1HG TCC of bladder underwent restaging TURB (ReTURB). Patients with muscle invasive disease at ReTURB underwent radical cystectomy; those with non-muscle invasive residual (NMI-RT) and those with no residual tumour (NRT) received an intravesical BCG therapy. We compared recurrence and progression in NMIRT patients and NRT patients at restaging TURB. Patients were followed every 3-6 months with cystoscopy and urine cytology. Results: 212 patients were enrolled in the study. At ReTURB, residual cancer was detected in 92 of 196 (46.9%) valuable patients: 14.3% of these were upstaged to T2. At follow up of 26.3 ± 22.8 months, there were differences in recurrence and progression rates between NRT and NMIRT patients: 26.9% and 45.3% (p < 0.001), 10.6% and 23.4% (p 0.03), respectively. Recurrence-free and progression-free survivals were significantly higher in NRT compared to NMIRT patients: 73.1% and 54.7% (p < 0.001), 89.4% and 76.6 (p 0.03), respectively. Conclusions: ReTURB allows to identify a considerable number of residual and understaged cancer. Patients with NMIRT on ReTURB have worse prognosis than those with NRT in terms of recurrence and progression free survival. These outcomes seem to suggest a prognostic impact of findings on ReTURB that could be a valid tool in management of high grade T1 TCC.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
10
Scopus
0
Google Scholar
Europe PMC
Md. Shafiqur Rahman, Sanjeeb Bhakta Bista, Md. Sayedul Islam, A. S. M. Shafiul Azam, Md. Shamim Hossain, Faika Farah Ahmed (2021)
RECURRENCE RATE AFTER REPEAT TRANSURETHRAL RESECTION AMONG PATIENTS WITH NEWLY DIAGNOSED T1 BLADDER CANCER. INDIAN JOURNAL OF APPLIED RESEARCH, 51.
10.36106/ijar/7213765
A. Brun, N. Koutlidis, T. Thibault, A. Escoffier, F. Bardet, L. Cormier (2023)
Résultats et impacts d’une résection de réévaluation dans le traitement des carcinomes urothéliaux de vessie pT1G3 : étude observationnelle. Progrès en Urologie, 33(3), 125.
10.1016/j.purol.2022.12.012
Yavuz Guler (2025)
Clinical and pathological risk factors for tumour recurrence and upstaging in second TURBT for patients with NMIBC: a systematic review and meta-analysis. Aktuelle Urologie, 56(01), 30.
10.1055/a-2063-3144
Takafumi Yanagisawa, Tatsushi Kawada, Markus von Deimling, Kensuke Bekku, Ekaterina Laukhtina, Pawel Rajwa, Marcin Chlosta, Benjamin Pradere, David D'Andrea, Marco Moschini, Pierre I. Karakiewicz, Jeremy Yuen-Chun Teoh, Jun Miki, Takahiro Kimura, Shahrokh F. Shariat (2024)
Repeat Transurethral Resection for Non–muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era. European Urology Focus, 10(1), 41.
10.1016/j.euf.2023.07.002
Lede Lin, Xiaotong Guo, Yucheng Ma, Jiang Zhu, Xiang Li (2023)
Does repeat transurethral resection of bladder tumor influence the diagnosis and prognosis of T1 bladder cancer? A systematic review and meta-analysis. European Journal of Surgical Oncology, 49(1), 29.
10.1016/j.ejso.2022.06.005
Angelo Naselli, Rodolfo Hurle, Stefano Paparella, Nicolò Maria Buffi, Giovanni Lughezzani, Giuliana Lista, Paolo Casale, Alberto Saita, Massimo Lazzeri, Giorgio Guazzoni (2018)
Role of Restaging Transurethral Resection for T1 Non–muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 4(4), 558.
10.1016/j.euf.2016.12.011
Marcus G.K. Cumberbatch, Beat Foerster, James W.F. Catto, Ashish M. Kamat, Wassim Kassouf, Ibrahim Jubber, Shahrokh F. Shariat, Richard J. Sylvester, Paolo Gontero (2018)
Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review. European Urology, 73(6), 925.
10.1016/j.eururo.2018.02.014
Hiroshi Kikuchi, Takashige Abe, Ryuji Matsumoto, Takahiro Osawa, Satoru Maruyama, Sachiyo Murai, Nobuo Shinohara (2022)
Outcomes of bacillus Calmette–Guérin therapy without a maintenance schedule for high‐risk non‐muscle‐invasive bladder cancer in the second transurethral resection era. International Journal of Urology, 29(3), 251.
10.1111/iju.14761
Sanchia S. Goonewardene, Raj Persad, Hanif Motiwala, David Albala (2020)
Management of Non-Muscle Invasive Bladder Cancer. 271.
10.1007/978-3-030-28646-0_55
Alexandre Guigui, Giuseppe Basile, Fabio Zattoni, Andrea Gallioli, Paolo Verri, Julia Aumatell, Bastien Gondran-Tellier, Eric Lechevallier, Cyrille Bastide, Alessandro Uleri, Michele Sica, Thibaut Long-Depaquit, Giuseppe Dinoi, Fabrizio Dal Moro, Akram Akiki, Harry Toledano, Pawel Rajwa, Francesco Montorsi, Daniele Amparore, Francesco Porpiglia, Alberto Breda, Marco Moschini, Michael Baboudjian (2024)
Prognostic significance of residual tumor at restaging transurethral bladder resection in high-risk non-muscle-invasive bladder cancer. World Journal of Urology, 42(1),
10.1007/s00345-024-05192-x

How to Cite

Sanseverino, R., Napodano, G., Campitelli, A., & Addesso, M. (2016). Prognostic impact of ReTURB in high grade T1 primary bladder cancer. Archivio Italiano Di Urologia E Andrologia, 88(2), 81–85. https://doi.org/10.4081/aiua.2016.2.81

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.